ProKidney Corp
PROK2.710USD
+0.180+7.11%
Fechamento 09/18, 16:00（ET）Cotações atrasadas em 15 min
361.57MValor de mercado
PerdaP/L TTM
Mais detalhes de ProKidney Corp Empresa
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Informações da empresa
Código da empresaPROK
Nome da EmpresaProKidney Corp
Data de listagemJun 30, 2021
CEODr. Bruce Culleton, M.D.
Número de funcionários204
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 30
Endereço2000 Frontis Plaza Blvd.
CidadeWINSTON-SALEM
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal27103
Telefone13369997028
Sitehttps://prokidney.com/
Código da empresaPROK
Data de listagemJun 30, 2021
CEODr. Bruce Culleton, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Lucio Tozzi
Mr. Lucio Tozzi
Senior Vice President - Global Clinical Operations
Senior Vice President - Global Clinical Operations
--
--
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 2 de set
Atualizado em: ter, 2 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Tolerantia LLC
16.75%
Suvretta Capital Management, LLC
9.14%
Control Empresarial de Capitales, S.A. de C.V.
7.94%
Morgan Stanley Investment Management Inc. (US)
4.23%
BlackRock Mexico Operadora SA de CV SOFI
2.54%
Outro
59.39%
Investidores
Investidores
Proporção
Tolerantia LLC
16.75%
Suvretta Capital Management, LLC
9.14%
Control Empresarial de Capitales, S.A. de C.V.
7.94%
Morgan Stanley Investment Management Inc. (US)
4.23%
BlackRock Mexico Operadora SA de CV SOFI
2.54%
Outro
59.39%
Tipos de investidores
Investidores
Proporção
Corporation
24.70%
Investment Advisor
10.51%
Hedge Fund
10.27%
Investment Advisor/Hedge Fund
5.98%
Research Firm
2.88%
Individual Investor
1.92%
Endowment Fund
0.74%
Family Office
0.04%
Bank and Trust
0.04%
Outro
42.93%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
2023Q3
236
64.28M
104.12%
-21.16M
2023Q2
223
59.02M
95.83%
-21.49M
2023Q1
183
53.54M
87.01%
-23.74M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Tolerantia LLC
22.62M
17.46%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
9.53%
--
--
Mar 31, 2025
Control Empresarial de Capitales, S.A. de C.V.
10.72M
8.28%
+2.28M
+27.04%
Apr 22, 2025
Morgan Stanley Investment Management Inc. (US)
10.04M
7.75%
-3.51M
-25.90%
Mar 31, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.65%
--
--
Mar 31, 2025
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.89%
--
--
May 31, 2025
Bleichroeder LP
2.00M
1.54%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
4.88%
+8.24K
+0.13%
Mar 31, 2025
The Vanguard Group, Inc.
5.21M
4.02%
-63.88K
-1.21%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
